Telsey Advisory lowered the firm’s price target on Waldencast (WALD) to $2 from $3 and keeps a Market Perform rating on the shares. The company’s Q4 results fell short of expectations, the analyst tells investors. Waldencast is still undergoing a strategic review, which has improved the balance sheet, but recent growth has been slower than expected, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast price target lowered to $2 from $4 at Canaccord
- Waldencast Posts Flat 2025 Results as Obagi Surges, Launches Strategic Review and Deleveraging Drive
- Waldencast reports Q4 revenue $72M vs. $72.1M last year
- Obagi Medical, Schweiger Dermatology collaborate for ALOHA program
- Obagi Medical, It’s a Secret Med Spa collaborate for ALOHA program